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The Hippo signaling pathway comprises a series of cytoplasmic tumor suppressor proteins
including Merlin and the Lats1/2 and MST1/2 kinases, and is thought to play a critical role
in determining the sizes of organs and tissues. The Hippo pathway is regulated upstream
by extracellular mechanosensory signaling arising from cell shape and polarity, as well as
by a variety of extracellular signaling molecules. When active, the pathway maintains the
transcriptional activators Yes-associated protein (YAP) and TAZ in phosphorylated forms in
the cytoplasm, preventing cell proliferation. When the Hippo pathway is inactivated, YAP
and TAZ are translocated to the nucleus and induce the expression of a variety of proteins
concerned with entry into the cell division cycle, such as cyclin D1 and Fox M1, as well
as the inhibition of apoptosis. The failure of the Hippo pathway has been implicated in the
development of many different types of cancer but there is limited information available
as to its involvement in melanoma. We hypothesize here firstly that the Hippo pathway is
involved in maintaining density of cutaneous melanocytes on the basement membrane at
the junction of the epidermis and the dermis, and secondly, that its function is disturbed
in melanoma. We have analyzed a series of 23 low passage human melanoma lines as
well as cultured normal melanoma, and find that melanocytes, as well as all melanoma cell
lines examined express TAZ. Melanocytes and most melanoma lines also express YAP. E-
cadherin, an upstream regulator of the Hippo pathway, and Axl, a receptor tyrosine kinase
regulated by the Hippo pathway, are expressed in melanocytes and in several melanoma
cell lines. These observations, together with published evidence for the presence of Mer-
lin, Lats1/2, and MST1/2 in melanocytes and melanoma cells, support the hypothesis that
the Hippo pathway is an important component of melanocyte and melanoma behavior.
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INTRODUCTION
The Hippo signaling pathway derives its name from the discov-
ery of a set of four genes in Drosophila that together were found
to control organ size. These genes specify a series of kinases and
adaptor proteins including Hippo (Hpo), Warts (Wts), and Sal-
vador (Sav), loss of function of which results in flies with enlarged,
folded eyes and excess head cuticle, a “hippopotamus-like” pheno-
type (Wu et al., 2003). Subsequent studies have demonstrated an
analogous pathway in humans, potentially providing an answer to
the long-standing question in biology of how organ size is stabi-
lized throughout life (Pan, 2012). In humans, mechanical signals
mediated by cell–cell contacts and by interactions with the extra-
cellular matrix generate signals which are integrated in space and
time and form the heart of the Hippo pathway (Halder et al., 2012).
Mechanical signals are complemented by those from membrane
receptors including G-protein coupled receptors (GPCRs), which
are known to respond to a number of ligands such as lysophospha-
tidic acid, sphingosine-1-phosphophate, glucagon, and epineph-
rine (Yu et al., 2011). Merlin, a product of the neurofibromatosis
type 2 (NF2) gene (Li et al., 2012), is a key component of the
pathway and associates with Kibra, a protein associated with
memory performance (Xiao et al., 2011) and with Expanded, a
tumor suppressor protein also associated with the Hippo pathway
(Hamaratoglu et al., 2006). The Kibra–Merlin-Expanded protein
complex leads to activation of the Hippo pathway by activating
Mammalian Sterile 20-like kinase (Mst1/2), a homolog of Hippo
in Drosophila, through autophosphorylation (Yu et al., 2010).
Mst1/2, complexed with the scaffold protein Sav1 (the analog of
Salvador), phosphorylates and activates the large tumor suppres-
sor (Lats1/2) kinase, which is the homolog of Warts in Drosophila
(Chan et al., 2005). Lats1/2 are also directly activated by the scaf-
fold protein, Msp-one binder (Mob1) (Zhao et al., 2011). Kibra
also contributes to the activation of Lats1/2 (Moleirinho et al.,
2013).
In a number of cell types Lats1/2 kinase has been found to
phosphorylate and inactivate the transcription co-activator Yes-
associated protein (YAP), the homolog of Yorkie in Drosophila,
as well as TAZ, the YAP paralog transcriptional co-activator with
PDZ-binding motif (Hao et al., 2008). Phosphorylation of YAP
at Ser127 by Lats1/2 generates a 14-3-3 binding site that leads to
YAP cytoplasmic sequestration through 14-3-3 binding and conse-
quent spatial separation from nuclear target transcription factors,
preventing entry into the cell division cycle (Zhao et al., 2007). Fur-
thermore, phosphorylation of YAP at Ser381, and of TAZ, leads to
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further changes and to ubiquitin-mediated proteasomal degrada-
tion (Zhao et al., 2010). Loss of phosphorylation allows YAP/TAZ
to enter the nucleus and initiate a complex cascade of transcription
events that lead to cell proliferation, cell migration, and suppres-
sion of anoikis, a form of apoptosis (Zhao et al., 2011). Merlin may
also act in a fashion similar to that of β-catenin, translocating to the
nucleus and stimulating transcription (Li et al., 2012). Expanded
also directly associates with Yorkie in Drosophila to inhibit growth
of the Hippo pathway by sequestering Yorkie in the cytoplasm
(Badouel et al., 2009).
Studies of the Hippo pathway suggest it has a three-dimensional
“sense” that is communicated across the whole organ and controls
both cell proliferation and apoptosis. A possible example of such
organ size control is provided by liver; it has been known for many
years that surgical reduction of liver volume leads to extensive cell
division and regeneration until the liver approaches its original
size. The Hippo pathway has been hypothesized to have a role in
this process (Avruch et al., 2011). In this review, we explore the
hypothesis that the Hippo pathway is responsible for determining
the overall number of cutaneous melanocytes and that changes in
this pathway contribute to the development of melanoma.
MELANOCYTES AND THEIR FUNCTIONS
Melanocytes are found in a number of locations including the eyes,
ears, and brain but are particularly noted for their ability to form a
two-dimensional network in skin at the junction of the dermis and
the epidermis. Melanocytes are localized on the basement mem-
brane, a layer of fibrous proteins which separates the dermis from
the epidermis, and have a density of approximately 1000 cells per
square millimeter (Gilchrest et al., 1979). This density is main-
tained throughout life. The skin comprises the epidermis, which
contains melanocytes, keratinocytes, and Langerhans cells, and
the dermis, which includes blood vessels, nerve cells, adipocytes,
macrophages, and fibroblasts (Norris, 2011). All three epidermal
cell types and many dermal cell types express toll-like receptors and
contribute to recognition of pathogens in host immunity (Hari
et al., 2010). Melanocytes on the basement membrane have the
additional function of synthesizing melanin and transporting it
in vesicles (melanosomes) to keratinocytes within the epidermis,
thus protecting the epidermis from ultraviolet light (UV)-induced
damage.
Epidermal melanocytes are strongly polarized and bind on one
face to laminin molecules of the basement membrane via integrins
including α3β1 and α6β1, and on the other face to other cells of
the epidermis through long processes called dendrites (Fukunaga-
Kalabis et al., 2006). Each melanocyte appears to interact with
several dozen keratinocytes (Haass et al., 2005), as shown diagram-
matically in Figure 1. Interestingly, when melanocytes are cultured
on Matrigel, a mixture of proteins which approximates the base-
ment membrane, they form a network of similar cell density, as
shown in Figure 2. Both melanocytes and keratinocytes express
E-cadherin and desmoglein, allowing the formation of adherens
junctions between them and probably also between melanocytes in
the network. The formation of dendrites, which may be controlled
by Rac1 (Scott and Cassidy, 1998), allows contact to be made with
multiple keratinocytes and the transport of melanosomes to the
outer layers of the skin.
STIMULATION OF MELANOCYTE PROLIFERATION
Melanocytes, like fibroblasts, normally exist in a quiescent state
but continuously preserve their ability to proliferate in response to
cell loss or injury. The local production of reactive oxygen species
(ROS) constitutes one of the main causes of cell injury and death
(Fried and Arbiser, 2008). Melanin production is itself associated
with free radical production (Arck et al., 2006) and environmental
UVA and UVB are known both to generate ROS (Noonan and De
Fabo, 2009) and to increase melanocyte density (Gilchrest et al.,
1979). Inflammatory processes in the skin in response to pathogens
FIGURE 1 | Diagram of a melanocyte on the basement membrane and
sandwiched between the epidermis and the dermis. Melanocytes extend
a number of dendrites into the epidermis and these serve to transfer
melanosomes from each melanocyte to a number of keratinocytes.
Connections between adjacent melanocytes also involve dendrites but are
not shown in the figure.
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FIGURE 2 | Phase contrast photomicrograph of normal melanocytes
growing on a layer of Matrigel.
also induce Langerhans cells and other epidermal cells to gener-
ate ROS. Replacement of melanocytes is an important facet of the
maintenance of the epidermis and the induction of melanocyte
proliferation may occur not only as a physiological response to
cell injury or loss but also as a result of an oncogenic event such
as an activating mutation. Examples of such events include acti-
vating mutations of the gene BRAF (Pollock et al., 2003), which
activate the MEK/ERK pathway? and activating mutations of the
gene PIK3CA, which activate the PI3K/AKT pathway (Hafner et al.,
2007). An important cellular response to such oncogenic events is
the induction of senescence. One potential cellular mechanism is
provided by the p130-E2F4-DREAM complex; loss of this function
leads to the activation of the protein p16, which mediates senes-
cence (Hauser et al.,2012). This and other mechanisms are thought
to contribute to the formation of moles or naevi, a collection of
senescent cells within the skin epidermis.
HYPOTHESIS: THE HIPPO PATHWAY IN MELANOCYTES
We hypothesize here that the overall density of melanocytes
throughout life is controlled by elements of the Hippo signaling
pathway. We suggest that mechanical signals mediated by con-
tacts between melanocytes and the basement membrane, other
melanocytes and keratinocytes are integrated in space and time
to activate the Hippo pathway, as has been suggested for other tis-
sues (Halder et al., 2012). Mechanical signals are complemented by
biochemical signals, particularly from keratinocytes, and relayed
from surface receptors, to cellular components through protein
phosphorylation. Some of the proposed upstream elements of
this hypothesis are shown in the simplified diagram in Figure 3.
Melanocytes are maintained in a physically stretched state by inter-
action of integrins with elements on the basement membrane, as
well as by the interaction of E-cadherin, desmoglein, and other
adhesion molecules on dendrites with other cells, particularly
adjacent keratinocytes; F-actin polymerization and depolymeriza-
tion are thought to contribute to the extension and retraction of
dendrites that interact with keratinocytes.
Melanocytes express E-cadherin, along with β-catenin and α-
catenin (Larue et al., 2003), which by analogy with other cell types
would be expected to interact with components of the cytoskele-
ton to form adherens junctions (Mareel et al., 1997; Shapiro and
Weis, 2009). Merlin is known to be expressed by melanoma cells
and may also be expressed by melanocytes; it is recruited to nascent
adherens junctions and may signal through MST1/2 (Murray et al.,
2012). Glutamate metabotropic receptors are GPCRs expressed
by melanocytes (Hoogduijn et al., 2006) and may provide a link
between glutamate, produced by keratinocytes, and Lats1/2 in an
analogous fashion to that proposed for other GPCRs (Yu et al.,
2011). Another potential link is the Axl receptor tyrosine kinase,
which is located on melanocytes (Sensi et al., 2011), is activated by
the expression of growth arrest-specific (GAS) factors produced
by keratinocytes (Manzow et al., 1996) and is regulated by the YAP
pathway (Xu et al., 2011).
A scheme whereby YAP and TAZ participate in the control of
proliferation of cultured melanocytes is shown in Figure 4. Sig-
nals for proliferation are provided by the culture substrate and
the specific components of the growth medium, and it is possible
in vivo that cell loss or injury results in loss of melanocyte con-
tacts with the basement membrane and/or other cells, inhibiting
LATS1/2 function and activating YAP/TAZ. Some of the down-
stream signaling pathways of activated YAP/TAZ are depicted in
Figure 4. Dephosphorylated YAP/TAZ enters the nucleus, bind-
ing to and activating TEAD transcription factors, which in turn
lead to increased transcription of target genes, increases in cell
motility, invasion, anchorage-independent growth and prolifera-
tion, and resistance to apoptosis (Mizuno et al., 2012; Zhao et al.,
2012). YAP-TEAD transcription induces CCND1, the gene encod-
ing cyclin D1 (Cao et al., 2008) and FOXM1, a gene encoding a
member of the Forkhead family of proteins (Mizuno et al., 2012).
Cyclin D1 activates cyclin-dependent kinases 4 and 6 (cdk4 and
cdk6), which in turn phosphorylate the retinoblastoma protein
(Rb), allowing activation of E2F transcription factors. FOXM1 reg-
ulates the cdc25B protein phosphatase, cyclin B, polo-like kinase,
aurora B kinase, and centromere proteins, controlling progression
through S-phase and mitosis as well as cell cycle transitions from
G1-phase to S-phase and from G2-phase to mitosis (Koo et al.,
2012).
Lats1/2 also activates the dual-specificity tyrosine
phosphorylation-regulated kinases (DYRK) (Tschop et al., 2011),
which in turn phosphorylate and activate multi-protein com-
plexes known as the p130-E2F4-DREAM (DP,retinoblastoma,E2F,
MuvB) repressor complexes. These silence E2F target gene expres-
sion (Dick and Mymryk, 2011; Tschop et al., 2011). Dephosphory-
lated DYRK is no longer able to activate the p130-E2F4-DREAM
complex, leading to derepression of transcription of genes under
the control of activating members of the E2F family (Tschop et al.,
2011), including cyclin E (Dick and Mymryk, 2011) and a num-
ber of proteins associated with DNA replication. Loss of Hippo
activity might thus constitute a selective pressure for the inactiva-
tion of p16-mediated suppression of proliferation signaling and
the emergence of melanoma cells. Several studies indicate the exis-
tence of cross-talk between the Hippo pathway and other signaling
pathways. For instance, YAP activation has been shown to alter the
function of the MAPK pathway (Kang et al., 2011). The Hippo
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FIGURE 3 | Diagram showing some of the upstream elements of the
proposed Hippo pathway. Melanocytes are strongly polarized and
receive signals on the one hand from the epidermis through adherens
junctions with keratinocytes, and on the other hand from the basement
membrane through integrins. They also receive signals through receptor
tyrosine kinases such as Axl and through G-protein coupled receptors
(GPCRs). All are likely to signal through kinases to Lats1/2; arrows indicate
signaling events.
pathway also inhibits the Wnt/β-catenin pathway by promoting
interaction between TAZ and the Disheveled (DVL) protein of the
Wnt pathway in the cytoplasm (Varelas et al., 2010; Azzolin et al.,
2012), indicating a role for the Hippo pathway in morphogenetic
signaling.
INVOLVEMENT OF THE HIPPO PATHWAY IN MELANOMA
To collect evidence for the involvement of the Hippo pathway in
melanoma, a series of melanoma lines developed in this labora-
tory (Marshall et al., 1993, 1994; Kim et al., 2012) were analyzed for
expression of some of the components and targets of the Hippo
pathway (Figure 5). Many of the melanoma lines have been found
to form networks on Matrigel (Zhao et al., 2005) in a manner
similar to that of melanocytes (Figure 2), suggesting that they
are capable of interaction with the extracellular matrix. Most of
the lines were tested for expression of E-cadherin and N-cadherin
(Kim et al., submitted), which are upstream elements of the Hippo
pathway. The majority of lines had lost E-cadherin expression and
replaced it with expression of N-cadherin, which is associated with
a more invasive phenotype (Qi et al., 2005); a small proportion of
cell lines expressed neither E-cadherin nor N-cadherin. All of the
melanoma lines tested strongly expressed TAZ and many addition-
ally expressed YAP. As shown in Figure 5, 35% of melanoma lines,
as well as normal melanocytes, expressed Axl although this was
not related to expression of cadherins. Another study reported
that 38% of melanoma lines expressed Axl and postulated that
expression was associated with motility and invasion (Sensi et al.,
2011).
It is known that from animal models of melanoma that pro-
liferation and invasiveness are promoted by YAP-TEAD (Lamar
et al., 2012) and inhibited by Merlin (Murray et al., 2012). CTGF
(Braig et al., 2011) and GLI2 (Alexaki et al., 2010), two genes
downstream of the YAP/TAZ-TEAD complex, have been associ-
ated with increased proliferation and invasiveness in melanoma.
Taken together, these results support the involvement of YAP and
TAZ in some stages of melanoma development. It is likely that
the microenvironment of the melanoma may also be involved in
YAP-TEAD regulation, for instance in the generation of ROS and
cytokines. Further research needs to be carried out to characterize
other elements of the Hippo pathway in melanoma, particularly
upstream elements such as Lats1/2.
Our previous studies have suggested that two changes may
be important to distinguish melanoma cell lines from cultured
melanocytes: the partial loss of serum dependence of some intra-
cellular signaling pathways (Kim et al., 2012) and the suppression
of the p16 inhibitory pathway (Charters et al., 2011), which is com-
mon in melanoma (Hauser et al., 2012). Melanomas, as opposed to
melanocytes, contain a number of mutated genes, raising the ques-
tion of whether any of these mutations can affect the integrity of
the Hippo pathway. Melanomas have a high frequency of mutant
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FIGURE 4 | Diagram showing some of the downstream elements of
the proposed Hippo pathway. The transcription factors YAP/TAZ-TEAD are
activated, and DYRK-DREAM is inactivated by loss of Hippo signalling.
Resulting transcription products are involved in regulating the synthesis of a
number of proteins associated with cell proliferation and migration.
BRAF mutations, and in papillary thyroid cancer, expression of
mutant BRAF is associated with inhibition of MST1/2 kinases
(Lee et al., 2011); it would be interesting to determine whether
this is also the case in melanoma. Moreover, BRAF mutations are
associated with a Rac-dependent cadherin switch in melanoma
(Monaghan-Benson and Burridge, 2013), suggesting a link to the
cytoskeleton. A survey of mutant genes in melanoma revealed a
high frequency of Rac1 mutations (Krauthammer et al., 2012);
Rac1 acts to modify the cytoskeleton and loss could potentially
change Hippo pathway regulation. The Ras association domain
family gene RASSF1 is frequently inactivated by promoter hyper-
methylation in a variety of human tumors including melanoma
(Spugnardi et al., 2003; Richter et al., 2009) and its protein prod-
uct RASSF is known to be a binding partner of MST1/2 kinases
(Khokhlatchev et al., 2002), again suggesting a link to the Hippo
pathway. The GRIN2 gene, which codes for a subunit of the glu-
tamate ionotropic receptor, is mutated in approximately 25% of
melanomas (Wei et al., 2012). This receptor is involved in modu-
lation of melanocyte dendrite morphology (Song et al., 2012) and
might therefore also affect the Hippo pathway. Mutations in the
NF2 gene, which encodes Merlin (Figure 3) have been reported in
a number of cancers including approximately 30% of melanomas
and could have an important role in the efficacy of the Hippo path-
way. Finally, FAT4 is known to inhibit cell growth by activation of
FIGURE 5 |Western blots of whole-cell extracts of cultures of normal
melanocytes and of a number of melanoma lines, indicating expression
ofYAP andTAZ. The numbers indicate the identities of members of the New
Zealand melanoma collection (e.g., 3=NZM3). Mel indicates data for normal
melanocytes. Data for expression on western blots of E-cadherin and Axl,
taken from another publication (Kim et al., submitted), are shown below the
NZM numbers; – expression not detected; +weak expression; ++strong
expression; nd not done.
www.frontiersin.org May 2013 | Volume 3 | Article 123 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kim et al. Hippo pathway in melanoma
the Hippo pathway and the FAT4 gene is recurrently mutated in
several types of human cancer including melanoma (Katoh, 2012).
CONCLUSION
One of the fascinating features of the Hippo pathway is that it
is able to integrate several different types of signaling, includ-
ing those induced by cellular shape and adhesion changes, stress
responses, and fluctuating concentrations of extracellular sig-
naling molecules. It mediates cellular decisions on the control
of proliferation, motility and cell death, and existing evidence
indicates a complex and possibly redundant series of intra-
cellular pathways (Halder et al., 2012). Melanomas are often
thought of as developing mainly as the result of multiple genetic
changes and a number of these may be linked to the function
of the Hippo pathway. Furthermore, there is a strong possibil-
ity that extracellular signaling from the melanoma microenvi-
ronment may be important in tumor progression. The path-
ways underlying transduction of mechanical and cytoskeletal
signals are now under intensive investigation and may pro-
vide a rich source of potential targets for the therapy of this
disease.
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